Home
ANAB
ANAB News

Latest AnaptysBio Inc. (ANAB) News on November 27, 2025

MT Newswires

3 days ago

AnaptysBio Presents Opportunity Despite 'Near-Term Turbulence' Amid Legal Dispute with GSK, Wedbush Says

AnaptysBio Reverses Higher After Trading Legal Barbs With Pharma Giant GSK

Investor's Business Daily

6 days ago

AnaptysBio Reverses Higher After Trading Legal Barbs With Pharma Giant GSK

MT Newswires

6 days ago

Sector Update: Health Care Stocks Rise Pre-Bell Friday

MT Newswires

6 days ago

Rate Cut Hopes Lift US Equity Futures Pre-Bell

MT Newswires

6 days ago

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday on Reignited Rate Cut Hopes

MT Newswires

6 days ago

Top Premarket Decliners

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

The Wall Street Journal

6 days ago

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

MT Newswires

6 days ago

AnaptysBio Files Complaint Alleging GSK's Tesaro Breached Jemperli Collaboration Deal

Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

a month ago

Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy?

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

GlobeNewswire

a month ago

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks

a month ago

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

MT Newswires

a month ago

Wedbush Raises Price Target on AnaptysBio to $70 From $45, Keeps Outperform Rating

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

GlobeNewswire

a month ago

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

MT Newswires

a month ago

Barclays Initiates AnaptysBio at Overweight With $78 Price Target

MT Newswires

6 months ago

Sector Update: Health Care Stocks Mixed Premarket Wednesday

MT Newswires

6 months ago

HC Wainwright Upgrades AnaptysBio to Buy From Neutral, $38 Price Target

MT Newswires

6 months ago

AnaptysBio Reports Durable Responses, Favorable Safety for Rosnilimab in Arthritis Trial

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

GlobeNewswire

6 months ago

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

GlobeNewswire

6 months ago

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now

Insider Monkey

7 months ago

AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now

Analysts Are Upgrading AnaptysBio, Inc. (NASDAQ:ANAB) After Its Latest Results

Simply Wall St.

7 months ago

Analysts Are Upgrading AnaptysBio, Inc. (NASDAQ:ANAB) After Its Latest Results

AnaptysBio First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.

7 months ago

AnaptysBio First Quarter 2025 Earnings: Beats Expectations

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

Zacks

7 months ago

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

7 months ago

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

GlobeNewswire

7 months ago

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?

Zacks

8 months ago

AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?

MT Newswires

8 months ago

AnaptysBio Approves $75 Million Buyback Plan; Shares Rise

Anaptys Announces Stock Repurchase Plan

GlobeNewswire

8 months ago

Anaptys Announces Stock Repurchase Plan

Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks

TipRanks

8 months ago

Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

Zacks

9 months ago

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

Anaptys Announces Participation in March Investor Conferences

GlobeNewswire

9 months ago

Anaptys Announces Participation in March Investor Conferences

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire

9 months ago

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data

TipRanks

9 months ago

Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

Zacks

9 months ago

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?

Zacks

9 months ago

AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?

AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial

Clinical Trials Arena

9 months ago

AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial

AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment

Investor's Business Daily

9 months ago

AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment

MT Newswires

9 months ago

AnaptysBio's Rheumatorid Arthritis Drug Meets Primary Endpoint in Phase 2 Trial; Shares Rise

MT Newswires

9 months ago

Top Premarket Gainers

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

GlobeNewswire

9 months ago

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

GlobeNewswire

10 months ago

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years ago

Simply Wall St.

10 months ago

Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years ago

MT Newswires

10 months ago

Correction: Wolfe Initiates Coverage on AnaptysBio With Outperform Rating, $25 Price Target

MT Newswires

10 months ago

Truist Securities Initiates Coverage on AnaptysBio With Outperform Rating, $25 Price Target

Vanda and AnaptysBio link for generalised pustular psoriasis therapy

Pharmaceutical Technology

10 months ago

Vanda and AnaptysBio link for generalised pustular psoriasis therapy

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

GlobeNewswire

10 months ago

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

MT Newswires

10 months ago

Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

GlobeNewswire

10 months ago

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Zacks

10 months ago

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry

Zacks

10 months ago

How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry

Big Biotech Fund Loads Up on a Stock That Surged in 2024, and a Loser

Barrons.com

a year ago

Big Biotech Fund Loads Up on a Stock That Surged in 2024, and a Loser

Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?

Zacks

a year ago

Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

a year ago

Truist Securities Cuts Price Target on AnaptysBio to $20 From $30, Maintains Hold Rating

MT Newswires

a year ago

UBS Adjusts AnaptysBio Price Target to $18 From $33, Maintains Neutral Rating

AnaptysBio Stock Down as Eczema Study Fails to Meet Goals

Zacks

a year ago

AnaptysBio Stock Down as Eczema Study Fails to Meet Goals

AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints

Clinical Trials Arena

a year ago

AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints

MT Newswires

a year ago

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires

a year ago

Sector Update: Health Care

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

Benzinga

a year ago

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

MT Newswires

a year ago

Top Midday Decliners

MT Newswires

a year ago

Update: AnaptysBio Shares Plunge After Announcing Phase 2B Trial in Atopic Dermatitis Failed to Meet Endpoints

MT Newswires

a year ago

Wedbush Cuts Price Target on AnaptysBio to $40 From $42, Maintains Outperform Rating

Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year?

Zacks

a year ago

Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year?

MT Newswires

a year ago

AnaptysBio Says Phase 2B Trial in Atopic Dermatitis Failed to Meet Endpoints

MT Newswires

a year ago

BTIG Downgrades AnaptysBio to Neutral From Buy

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Zacks

a year ago

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Simply Wall St.

a year ago

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

a year ago

AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?

Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)

Zacks

a year ago

Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)

AnaptysBio Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

a year ago

AnaptysBio Third Quarter 2024 Earnings: Beats Expectations

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates

Zacks

a year ago

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Participation in November and December Investor Conferences

GlobeNewswire

a year ago

Anaptys Announces Participation in November and December Investor Conferences

MT Newswires

a year ago

AnaptysBio Shares Fall After Eli Lilly Removes Arthritis Drug Peresolimab From Pipeline

Anaptys Announces Participation in September Investor Conferences

GlobeNewswire

a year ago

Anaptys Announces Participation in September Investor Conferences

Why AnaptysBio Was Such a Healthy Stock This Week

Motley Fool

a year ago

Why AnaptysBio Was Such a Healthy Stock This Week

MT Newswires

a year ago

Truist Adjusts Price Target on AnaptysBio to $30 From $20, Maintains Hold Rating

AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering

Investor's Business Daily

a year ago

AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering

MT Newswires

a year ago

AnaptysBio Prices $100 Million Common Stock Offering

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

GlobeNewswire

a year ago

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Investors in AnaptysBio (NASDAQ:ANAB) have seen respectable returns of 74% over the past year

Simply Wall St.

a year ago

Investors in AnaptysBio (NASDAQ:ANAB) have seen respectable returns of 74% over the past year

MT Newswires

a year ago

Wedbush Adjusts Price Target on AnaptysBio to $42 From $34, Maintains Outperform Rating

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates

Zacks

a year ago

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

a year ago

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Zacks

a year ago

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Benzinga

a year ago

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

Is HCA Healthcare (HCA) Stock Outpacing Its Medical Peers This Year?

Zacks

a year ago

Is HCA Healthcare (HCA) Stock Outpacing Its Medical Peers This Year?

MT Newswires

a year ago

JPMorgan Upgrades AnaptysBio to Overweight From Neutral, Adjusts Price Target to $69 From $29

Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?

Zacks

a year ago

Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?

Industry Analysts Just Upgraded Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts By 16%

Simply Wall St.

2 years ago

Industry Analysts Just Upgraded Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts By 16%

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

Zacks

2 years ago

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

2 years ago

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

GlobeNewswire

2 years ago

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

GlobeNewswire

2 years ago

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

2 years ago

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?

Zacks

2 years ago

AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?

Actym Therapeutics Appoints Thomas Smart as CEO

PR Newswire

2 years ago

Actym Therapeutics Appoints Thomas Smart as CEO

Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

Motley Fool

2 years ago

Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.

Zacks

2 years ago

Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.

Share on Social Networks: